Crenolanib is a tyrosine kinase inhibitor that acts by specifically inhibiting the receptor tyrosine kinases PDGFRa and PDGFRb. Crenolanib inhibits the activity of PDGFRa D842V kinase and prevented the phosphorylation of wild type PDGFRa. Crenolanib possesses potential antineoplastic activity. Crenolanib is believed to suppress PDGFR-related signal transduction pathways leading to the inhibition of tumor angiogenesis and tumor cell proliferation.
Form:
White to Off-White Solid
Melting Point:
217-220 degrees C
Solubility:
DMSO, Methanol